A Phase 2 interventional study of Nivolumab and Ipilimumab in Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 35 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-20.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 43 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 29th largest by enrollment, is one of 24 that started in 2017, is one of 66 in phase 2, and was the 33rd registered.
7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Liza Villaruz, MD · Sites in United States
Ages 18+
Diwakar Davar · Sites in United States
Ages 18+
EuroCityClinic LLC · Sites in Russia
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 78 · Phase 3 24 · Phase 4 2
First in 2006; this study’s year is marked. 24 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 230 is above the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 66 across the 120 interventional studies. Of the 63 that completed or were terminated, 44 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 120 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb: 21 open now, 35 under way, 10 of them phase 3. Of 91 finished, 47 (52%) have results posted.
Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 45th largest by enrollment of the 107 interventional ones that give a count, is one of 9 that started in 2017, is one of 32 in phase 2, and was the 58th registered.
Bristol-Myers Squibb’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
13 of the studies testing nivolumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02595944Phase 3National Cancer Institute (NCI)Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) | 2027-05-31 |
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
| NCT05597800Universita di VeronaNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | 2026-12-31 |
| NCT06946797Bristol-Myers SquibbA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | 2027-02-05 |
| NCT06275360VA Office of Research and DevelopmentRepositioning Immunotherapy in VetArans With Lung Cancer | 2027-02-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Bristol-Myers Squibb’s 131 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to explore the possible links between participant characteristics and their cancer, with how effective the combination of nivolumab with ipilimumab is, in participants with Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nivolumab + Ipilimumab
Biological: Nivolumab · Biological: Ipilimumab
Specified dose on specified days
Also known as: Opdivo, BMS-936558
Specified dose on specified days
Also known as: Yervoy, BMS-734016
Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) Within PD-L1 Subgroup (TMB Cut-point = 16 Mutations/MB)
Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \<10 mm. Blood tumor mutational burden (bTMB) is the total number of nonsynonymous somatic mutations produced by a tumor that are detected in serum. CR+PR, confidence interval based on the Clopper and Pearson method.
Time frame: From first dose up to the date of objectively documented progression, or the date of initiation of palliative local therapy or the date of initiation of subsequent anticancer therapy (up to approximately 58 months)
Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) Within PD-L1 Subgroup (Blood TMB Cut-point = 21-mutations/MB)
Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \<10 mm. Blood tumor mutational burden (bTMB) is the total number of nonsynonymous somatic mutations produced by a tumor that are detected in serum. CR+PR, confidence interval based on the Clopper and Pearson method.
Time frame: From first dose up to the date of objectively documented progression, or the date of initiation of palliative local therapy or the date of initiation of subsequent anticancer therapy (up to approximately 58 months)
Objective Response Rate (ORR) Per Investigator by Tissue TMB Within PD-L1 Subgroup (Tissue TMB Cut-point = 10-mutations/MB)
Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \<10 mm. Tissue tumor mutational burden (tTMB) is the total number of nonsynonymous somatic mutations produced by a tumor that are detected in tumor tissue samples. CR+PR, confidence interval based on the Clopper and Pearson method.
Time frame: From first dose up to the date of objectively documented progression, or the date of initiation of palliative local therapy or the date of initiation of subsequent anticancer therapy (up to approximately 58 months)
Objective Response Rate (ORR) for All Treated Participants by Investigator Per RECIST 1.1
Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Complete Response (CR) is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \<10 mm. CR+PR, confidence interval based on the Clopper and Pearson method.
Time frame: From first dose until the date of objectively documented progression, or the date of initiation of palliative local therapy or the date of initiation of subsequent anticancer therapy, whichever occurs first (Up to approximately 67 months)
Disease Control Rate (DCR) for Part 1
Disease control rate (DCR) is the percent of treated participants with a best overall response of a complete response (CR), partial response (PR), or stable disease (SD), assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). PR is at least a 30% decrease in the sum of diameters of target lesions, using the baseline sum diameters as reference. CR is disappearance of all target lesions and a reduction in short axis to \<10 mm of any pathological lymph nodes (target or non-target). SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking smallest sum diameters as reference. PD is at least a 20% increase in the sum of diameters of target lesions, taking the smallest sum as reference. The sum must also demonstrate an absolute increase of at least 5 mm. (one or more new lesions is also considered progression). CR+PR, confidence interval based on the Clopper and Pearson method.
Time frame: From first dose until the date of objectively documented progression, or the date of initiation of palliative local therapy or the date of initiation of subsequent anticancer therapy, whichever occurs first (Up to approximately 67 months)
Duration of Response (DOR) for Part 1
DOR is the time between first confirmed response (Complete/Partial Response) and first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who don't progress or die are censored on the date of their last evaluable tumor assessment. Participants who started subsequent anti-cancer therapy without prior reported progression were censored at the last evaluable tumor assessment prior to or on the date of subsequent anti-cancer therapy. PR is at least 30% decrease in the sum of diameters of target lesions, using baseline sum diameters as reference. CR is disappearance of all target lesions and reduction in short axis to \<10 mm of any pathological lymph nodes (target or non-target). Progressive Disease (PD) is at least 20% increase in the sum of diameters of target lesions, taking the smallest sum as reference. The sum must also show an overall increase of \> 5 mm. (one or more new lesions is also progression). Median computed using Kaplan-Meier method.
Time frame: From first dose to the date of the first documented tumor progression or death due to any cause (Up to approximately 67 months)
Time to Response (TTR) for Part 1
TTR is the time taken from first dosing date to the time the criteria for Complete Response (CR)/Partial Response (PR) are first met. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.
Time frame: From first dose to the time the criteria for Complete Response/Partial Response are first met (Up to approximately 67 months)
Progression Free Survival (PFS)
PFS is defined as the time from first dosing date to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who neither progress nor die will be censored on the date of their last evaluable tumor assessment. Participants who started any subsequent anti-cancer therapy without a prior reported progression will be censored at the last evaluable tumor assessment prior to or on the date of initiation of subsequent anti-cancer therapy. Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking the smallest sum on study as reference. The sum must also show an overall increase of \> 5 mm. (one or more new lesions is also progression). Median calculated using Kaplan-Meier estimates.
Time frame: From first dose to the date of the first documented tumor progression or death due to any causes (Assessed up to approximately 67 months)
Overall Survival (OS)
OS is defined as the time from first dosing date to the date of death. If a participant didn't die, OS will be censored on the last date the participant was known to be alive. Median based on Kaplan-Meier estimates.
Time frame: From first dose to the date of death (Assessed up to approximately 67 months)
Number of Participants With Adverse Events (AEs) for Study Part 2
An Adverse Event (AE) is any new untoward medical occurrence or worsening preexisting medical condition in a treated participant and that does not necessarily have a causal relationship with treatment. An AE can be any unfavorable, unintended sign, symptom, or disease temporally associated with the use of treatment, whether or not related to the treatment.
Time frame: From first dose to 30 days after last dosing date (assessed up to approximately 27 months)
Number of Participants With Serious Adverse Events (SAEs) for Study Part 2
A Serious Adverse Event (SAE) results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), or requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: From first dose to 30 days after last dosing date (assessed up to approximately 27 months)
Number of Participants With Select Adverse Events (AEs) for Study Part 2
An Adverse Event (AE) is any new untoward medical occurrence or worsening preexisting medical condition in a treated participant and that does not necessarily have a causal relationship with treatment. An AE can be any unfavorable, unintended sign, symptom, or disease temporally associated with the use of treatment, whether or not related to the treatment.
Time frame: From first dose to 30 days after last dosing date (up to approximately 27 months)
In Part 1, upon determination of PD-L1 status (cut-off of 1%), 2 cohorts were defined: PD-L1 positive and negative. In Part 2, a separate group of participants were treated regardless of their PD-L1 status.
| Milestone | PART 1: PD-L1+ Status | PART 1: PD-L1- Status | PART 1: Not Evaluable/Indeterminate PD-L1 Status | PART 2: PD-L1 Status Independent |
|---|---|---|---|---|
| Started | 31 | 28 | 1 | 170 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 31 | 28 | 1 | 170 |
| Withdrew: Death | 1 | 0 | 0 | 3 |
| Withdrew: Participant withdrew consent | 0 | 1 | 0 | 5 |
| Withdrew: Other reasons | 1 | 2 | 0 | 5 |
| Withdrew: Administrative reason by sponsor | 0 | 0 | 0 | 1 |
| Withdrew: Participant requested to discontinue study treatment | 0 | 0 | 0 | 2 |
| Withdrew: Not reported | 0 | 0 | 0 | 6 |
| Withdrew: Maximum clinical benefit | 2 | 3 | 0 | 10 |
| Withdrew: Ae unrelated to study drug | 3 | 3 | 0 | 11 |
| Withdrew: Study drug toxicity | 8 | 5 | 0 | 37 |
| Withdrew: Disease progression | 16 | 14 | 1 | 90 |
Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \<10 mm. Blood tumor mutational burden (bTMB) is the total number of nonsynonymous somatic mutations produced by a tumor that are detected in serum. CR+PR, confidence interval based on the Clopper and Pearson method.
| Percent of Participants | PART 1: PD-L1 + Status | PART 1: PD-L1- Status | PART 1: Not Evaluable/Indeterminate PD-L1 Status | PART 2: PD-L1+ Status | PART 2: PD-L1- Status |
|---|---|---|---|---|---|
| bTMB High (Cut-point = 16-mutations) | 30 (6.7 to 65.2) | 50 (18.7 to 81.3) | — | 58.8 (32.9 to 81.6) | 30.3 (15.6 to 48.7) |
| bTMB Low (Cut-point = 16-mutations) | 33.3 (7.5 to 70.1) | 33.3 (4.3 to 77.7) | — | 31.8 (13.9 to 54.9) | 24.1 (10.3 to 43.5) |
Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \<10 mm. Blood tumor mutational burden (bTMB) is the total number of nonsynonymous somatic mutations produced by a tumor that are detected in serum. CR+PR, confidence interval based on the Clopper and Pearson method.
| Percent of Participants | PART 1: PD-L1+ Status | PART 1: PD-L1- Status | PART 1: Not Evaluable/Indeterminate PD-L1 Status | PART 2: PD-L1 + Status | PART 2: PD-L1- Status |
|---|---|---|---|---|---|
| bTMB High (Cut-point = 21-mutations) | 33.3 (4.3 to 77.7) | 66.7 (22.3 to 95.7) | — | 64.3 (35.1 to 87.2) | 40.9 (20.7 to 63.6) |
| bTMB Low (Cut-point = 21-mutations) | 30.8 (9.1 to 61.4) | 30.0 (6.7 to 65.2) | — | 32.0 (14.9 to 53.5) | 20.0 (9.1 to 35.6) |
Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \<10 mm. Tissue tumor mutational burden (tTMB) is the total number of nonsynonymous somatic mutations produced by a tumor that are detected in tumor tissue samples. CR+PR, confidence interval based on the Clopper and Pearson method.
| Percent of Participants | PART 1: PD-L1+ Status | PART 1: PD-L1- Status | PART 1: Not Evaluable/Indeterminate PD-L1 Status | PART 2: PD-L1 + Status | PART 2: PD-L1- Status |
|---|---|---|---|---|---|
| tTMB High (Cut-point = 10-mutations) | 25.0 (3.2 to 65.1) | 71.4 (29.0 to 96.3) | — | 60.0 (32.3 to 83.7) | 46.7 (21.3 to 73.4) |
| tTMB Low (Cut-point = 10-mutations | 27.3 (6.0 to 61.0) | 22.2 (2.8 to 60.0) | — | 25.0 (7.3 to 52.4) | 21.4 (10.3 to 36.8) |
Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Complete Response (CR) is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \<10 mm. CR+PR, confidence interval based on the Clopper and Pearson method.
| Percent of Participants | PART 1: PD-L1+ Status | PART 1: PD-L1- Status | PART 1: Not Evaluable/Indeterminate PD-L1 Status | PART 2: PD-L1 Status Independent |
|---|---|---|---|---|
| Objective Response Rate (ORR) for All Treated Participants by Investigator Per RECIST 1.1 | 29.0 (14.2 to 48.0) | 39.3 (21.5 to 59.4) | 0 (0.0 to 97.5) | 29.4 (22.7 to 36.9) |
Disease control rate (DCR) is the percent of treated participants with a best overall response of a complete response (CR), partial response (PR), or stable disease (SD), assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). PR is at least a 30% decrease in the sum of diameters of target lesions, using the baseline sum diameters as reference. CR is disappearance of all target lesions and a reduction in short axis to \<10 mm of any pathological lymph nodes (target or non-target). SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking smallest sum diameters as reference. PD is at least a 20% increase in the sum of diameters of target lesions, taking the smallest sum as reference. The sum must also demonstrate an absolute increase of at least 5 mm. (one or more new lesions is also considered progression). CR+PR, confidence interval based on the Clopper and Pearson method.
| Percent of Participants | PART 1: PD-L1+ Status | PART 1: PD-L1- Status | PART 1: Not Evaluable/Indeterminate PD-L1 Status |
|---|---|---|---|
| Disease Control Rate (DCR) for Part 1 | 58.1 (39.1 to 75.5) | 64.3 (44.1 to 81.4) | 100.0 (2.5 to 100.0) |
DOR is the time between first confirmed response (Complete/Partial Response) and first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who don't progress or die are censored on the date of their last evaluable tumor assessment. Participants who started subsequent anti-cancer therapy without prior reported progression were censored at the last evaluable tumor assessment prior to or on the date of subsequent anti-cancer therapy. PR is at least 30% decrease in the sum of diameters of target lesions, using baseline sum diameters as reference. CR is disappearance of all target lesions and reduction in short axis to \<10 mm of any pathological lymph nodes (target or non-target). Progressive Disease (PD) is at least 20% increase in the sum of diameters of target lesions, taking the smallest sum as reference. The sum must also show an overall increase of \> 5 mm. (one or more new lesions is also progression). Median computed using Kaplan-Meier method.
| Months | PART 1: PD-L1+ Status | PART 1: PD-L1- Status | PART 1: Not Evaluable/Indeterminate PD-L1 Status |
|---|---|---|---|
| Duration of Response (DOR) for Part 1 | 24.56 (1.9 to 61.7) | 29.57 (2.8 to 48.9) | — |
TTR is the time taken from first dosing date to the time the criteria for Complete Response (CR)/Partial Response (PR) are first met. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.
| Months | PART 1: PD-L1+ Status | PART 1: PD-L1- Status | PART 1: Not Evaluable/Indeterminate PD-L1 Status |
|---|---|---|---|
| Time to Response (TTR) for Part 1 | 1.84 (1.6 to 3.7) | 5.26 (1.7 to 18.5) | — |
PFS is defined as the time from first dosing date to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who neither progress nor die will be censored on the date of their last evaluable tumor assessment. Participants who started any subsequent anti-cancer therapy without a prior reported progression will be censored at the last evaluable tumor assessment prior to or on the date of initiation of subsequent anti-cancer therapy. Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking the smallest sum on study as reference. The sum must also show an overall increase of \> 5 mm. (one or more new lesions is also progression). Median calculated using Kaplan-Meier estimates.
| Months | PART 1: PD-L1+ Status | PART 1: PD-L1- Status | PART 1: Not Evaluable/Indeterminate PD-L1 Status | PART 2: PD-L1 Status Independent |
|---|---|---|---|---|
| Progression Free Survival (PFS) | 3.71 (1.97 to 8.90) | 4.30 (1.84 to 13.60) | 3.61 (NA to NA) | 6.28 (5.09 to 7.56) |
OS is defined as the time from first dosing date to the date of death. If a participant didn't die, OS will be censored on the last date the participant was known to be alive. Median based on Kaplan-Meier estimates.
| Months | PART 1: PD-L1+ Status | PART 1: PD-L1- Status | PART 1: Not Evaluable/Indeterminate PD-L1 Status | PART 2: PD-L1 Status Independent |
|---|---|---|---|---|
| Overall Survival (OS) | 9.63 (4.47 to 20.57) | 22.29 (11.56 to 25.23) | 9.23 (NA to NA) | 14.78 (11.99 to 20.60) |
An Adverse Event (AE) is any new untoward medical occurrence or worsening preexisting medical condition in a treated participant and that does not necessarily have a causal relationship with treatment. An AE can be any unfavorable, unintended sign, symptom, or disease temporally associated with the use of treatment, whether or not related to the treatment.
| Participants | PART 2: PD-L1 Status Independent |
|---|---|
| Number of Participants With Adverse Events (AEs) for Study Part 2 | 169 |
A Serious Adverse Event (SAE) results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), or requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | PART 2: PD-L1 Status Independent |
|---|---|
| Number of Participants With Serious Adverse Events (SAEs) for Study Part 2 | 102 |
An Adverse Event (AE) is any new untoward medical occurrence or worsening preexisting medical condition in a treated participant and that does not necessarily have a causal relationship with treatment. An AE can be any unfavorable, unintended sign, symptom, or disease temporally associated with the use of treatment, whether or not related to the treatment.
| Participants | PART 2: PD-L1 Status Independent |
|---|---|
| Gastrointestinal Adverse Events | 68 |
| Hepatic Adverse Events | 49 |
| Pulmonary Adverse Events | 17 |
| Renal Adverse Events | 28 |
| Skin Adverse Events | 73 |
| Hypersensitivity/Infusion Reaction | 12 |
Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \<10 mm. Blood tumor mutational burden (bTMB) is the total number of nonsynonymous somatic mutations produced by a tumor that are detected in serum. CR+PR, confidence interval based on the Clopper and Pearson method.
| Percent of Participants | PART 1 | PART 1: Not Evaluable/Indeterminate PD-L1 Status | PART 2 |
|---|---|---|---|
| bTMB High (Cut-point = 16-mutations) | 40.0 (19.1 to 63.9) | — | 34.4 (22.9 to 47.3) |
| bTMB Low (Cut-point = 16-mutations) | 25.0 (7.3 to 52.4) | — | 26.9 (16.8 to 39.1) |
Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \<10 mm. Blood tumor mutational burden (bTMB) is the total number of nonsynonymous somatic mutations produced by a tumor that are detected in serum. CR+PR, confidence interval based on the Clopper and Pearson method.
| Percent of Participants | PART 1 | PART 1: Not Evaluable/Indeterminate PD-L1 Status | PART 2 |
|---|---|---|---|
| bTMB High (Cut-point = 21-mutations) | 50.0 (21.1 to 78.9) | — | 44.4 (29.6 to 60.0) |
| bTMB Low (Cut-point = 21-mutations) | 25.0 (9.8 to 46.7) | — | 23.3 (14.8 to 33.6) |
Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \<10 mm. Tissue tumor mutational burden (tTMB) is the total number of nonsynonymous somatic mutations produced by a tumor that are detected in tumor tissue samples. CR+PR, confidence interval based on the Clopper and Pearson method.
| Percent of Participants | PART 1 | PART 1: Not Evaluable/Indeterminate PD-L1 Status | PART 2 |
|---|---|---|---|
| tTMB High (Cut-point = 10-mutations) | 46.7 (21.3 to 73.4) | — | 50.0 (32.4 to 67.6) |
| tTMB Low (Cut-point = 10-mutations | 20.0 (5.7 to 43.7) | — | 19.4 (10.8 to 30.9) |
Collected over Participants were assessed for all-cause mortality from their first dose to their study completion (up to approximately 67 months.) SAEs and Other AEs was assessed from first dose to 100 days post the last dose of study therapy (up to approximately an average of 8 months and a maximum of 29 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PART 1: PD-L1+ Status | 27/31 (87.1%) | 24/31 (77.4%) | 31/31 (100%) |
| PART 1: PD-L1- Status | 22/28 (78.6%) | 14/28 (50%) | 27/28 (96.4%) |
| PART 1: Not Evaluable/Indeterminate PD-L1 Status | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| PART 2: PD-L1 Status Independent | 134/170 (78.8%) | 113/170 (66.5%) | 161/170 (94.7%) |
| Event | PART 1: PD-L1+ Status | PART 1: PD-L1- Status | PART 1: Not Evaluable/Indeterminate PD-L1 Status | PART 2: PD-L1 Status Independent |
|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 10/31 | 5/28 | 0/1 | 38/170 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/31 | 3/28 | 0/1 | 10/170 |
| Amylase increasedInvestigations | 3/31 | 0/28 | 0/1 | 0/170 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 3/31 | 2/28 | 0/1 | 7/170 |
| Urinary tract infectionInfections and infestations | 1/31 | 2/28 | 0/1 | 1/170 |
| HypokalaemiaMetabolism and nutrition disorders | 0/31 | 2/28 | 0/1 | 1/170 |
| Alanine aminotransferase increasedInvestigations | 2/31 | 0/28 | 0/1 | 2/170 |
| Lipase increasedInvestigations | 2/31 | 0/28 | 0/1 | 1/170 |
| Metabolic encephalopathyNervous system disorders | 2/31 | 0/28 | 0/1 | 0/170 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/31 | 0/28 | 0/1 | 1/170 |
| Event | PART 1: PD-L1+ Status | PART 1: PD-L1- Status | PART 1: Not Evaluable/Indeterminate PD-L1 Status | PART 2: PD-L1 Status Independent |
|---|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 6/31 | 10/28 | 1/1 | 43/170 |
| FatigueGeneral disorders | 18/31 | 16/28 | 0/1 | 43/170 |
| DiarrhoeaGastrointestinal disorders | 7/31 | 12/28 | 0/1 | 65/170 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 8/31 | 12/28 | 0/1 | 45/170 |
| NauseaGastrointestinal disorders | 12/31 | 11/28 | 0/1 | 48/170 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/31 | 10/28 | 0/1 | 45/170 |
| ConstipationGastrointestinal disorders | 6/31 | 9/28 | 0/1 | 25/170 |
| Decreased appetiteMetabolism and nutrition disorders | 9/31 | 9/28 | 0/1 | 38/170 |
| RashSkin and subcutaneous tissue disorders | 7/31 | 8/28 | 0/1 | 42/170 |
| Lipase increasedInvestigations | 6/31 | 7/28 | 0/1 | 28/170 |
| Age, Categorical(Participants) | PART 1: PD-L1+ Status | PART 1: PD-L1- Status | PART 1: Not Evaluable/Indeterminate PD-L1 Status | PART 2: PD-L1 Status Independent | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 15 | 0 | 76 | 101 |
| >=65 years | 21 | 13 | 1 | 94 | 129 |
| Sex: Female, Male(Participants) | PART 1: PD-L1+ Status | PART 1: PD-L1- Status | PART 1: Not Evaluable/Indeterminate PD-L1 Status | PART 2: PD-L1 Status Independent | Total |
|---|---|---|---|---|---|
| Female | 15 | 11 | 0 | 54 | 80 |
| Male | 16 | 17 | 1 | 116 | 150 |
| Ethnicity (NIH/OMB)(Participants) | PART 1: PD-L1+ Status | PART 1: PD-L1- Status | PART 1: Not Evaluable/Indeterminate PD-L1 Status | PART 2: PD-L1 Status Independent | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 4 | 6 |
| Not Hispanic or Latino | 24 | 25 | 1 | 98 | 148 |
| Unknown or Not Reported | 6 | 2 | 0 | 68 | 76 |
| Race/Ethnicity, Customized(Participants) | PART 1: PD-L1+ Status | PART 1: PD-L1- Status | PART 1: Not Evaluable/Indeterminate PD-L1 Status | PART 2: PD-L1 Status Independent | Total |
|---|---|---|---|---|---|
| White | 27 | 25 | 1 | 164 | 217 |
| Black or African American | 3 | 3 | 0 | 5 | 11 |
| Other | 1 | 0 | 0 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2017 to primary completion in Feb 2022, 58 months.
Results were first posted in Jun 2023, 1 year 3 months after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 58 months is above that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Ipilimumab
Carcinoma, Non-Small-Cell Lung →